29 April 2008: NorDiag ASA invites to a breakfast presentation of the first quarter 2008 on May 8 2008 at 8:30am, at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo.
 
Please confirm your participation to elin.flo@nordiag.com or by calling 55 54 39 60. Shareholders who wish to receive the quarterly report by mail are requested to send an email regarding this to the same email address.
 
Representatives from the Company will be CEO Mårten Wigstøl and CFO Tone Kvåle.
 
The first quarter report and the presentation will be published on NorDiag`s homepage www.nordiag.com.
 
Contact:
CEO Mårten Wigstøl, phone 911 65775
or
CFO Tone Kvåle, phone 915 19576.
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Read the Stock Exchange Notice here

Read the Stock Exchange Notice in Norwegian here